Galovan Scott Michael 4

What Happened

• Scott Michael Galovan, Chief Financial Officer of Avanos Medical (AVNS), had 5,907 performance-based RSUs convert into 5,907 shares on 2026-03-06 (reported 2026-03-10). Those shares are reported at $13.79 each for a total value of $81,458. To satisfy tax-withholding obligations tied to vesting events, he surrendered a total of 5,454 shares in three withholding transactions (2,356; 1,057; 2,041 shares) at $13.79 per share (totaling $32,489 + $14,576 + $28,145 = $75,210). Net increase in shares from these filings = 453 shares.

Key Details

• Transaction date(s): March 6, 2026; filing date: March 10, 2026 (filed within the SEC two-business-day Form 4 window).
• Price per share for all reported lines: $13.79.
• Acquired: 5,907 shares (code M — conversion/exercise of derivative / vesting of PRSUs) — $81,458 value.
• Disposed (to cover taxes; code F): 2,356 shares ($32,489), 1,057 shares ($14,576), 2,041 shares ($28,145) — total $75,210.
• Shares owned after transaction: not specified in the provided filing details.
• Relevant footnotes: F1–F4 indicate these were performance-based RSUs (PRSUs) and time-based RSUs (TRSUs) awarded previously (March 6, 2023 and March 6, 2024) and vested on March 6, 2026; the disposals reflect shares surrendered to the issuer to satisfy tax withholding.

Context

• This filing documents routine vesting and tax-withholding activity, not an open-market purchase or discretionary sale. Converting RSUs/PRSUs into shares and surrendering some shares to cover taxes (a cashless/withholding settlement) is a common practice and does not necessarily indicate a buy or sell decision by the insider. Purchases would be a clearer bullish signal; this report primarily shows compensation vesting and standard tax withholding.